Risk of Guillain-Barré Syndrome After Meningococcal Conjugate Vaccination
A meningococcal conjugate vaccine (MCV4) was introduced in the United States in 2005. Shortly after, case reports of Guillain-Barré syndrome (GBS), a serious demyelinating disease, began to be reported to the Vaccine Adverse Event Reporting System. In 2006, the US Centers for Disease Control and Prevention and the US Food and Drug Administration requested the evaluation of GBS risk after MCV4 vaccination. The authors of this article, published in Pharmacoepidemiology and Drug Safety, conducted a study to assess the risk of GBS after MCV4 vaccination. They found that among members of five US health plans, MCV4 vaccination was not associated with increased GBS risk. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Velentgas P, Amato AA, Bohn RL, et al.
Visit web page (English)
(Located at onlinelibrary.wiley.com)
Citation: Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barré Syndrome After Meningococcal Conjugate Vaccination. Pharmacoepidemiology and Drug Safety. 2012;21(12):1350-1358.